Rna Medicines Provider Orbital Therapeutics Scores $270M Series A

Apr 26, 2023•over 2 years ago

Amount Raised

$270 Million

Round Type

series a

Cambridge

Investors

Arch Venture Partners

Description

ARCH Venture Partners led the round.

Company Information

Company

Orbital Therapeutics

Location

Cambridge, Maryland, United States

About

Orbital Therapeutics aims to enhance global health by unleashing the full potential of RNA-based medicines (excluding RNAi therapeutics) to treat human disease in ways that were not previously possible. We’re building a first-in-kind platform designed to sit at the intersection of RNA technology delivery methods, data science and automation to develop an expansive portfolio of medicines, initially focused in the areas of vaccines, immunomodulation, protein replacement and regenerative medicine. Founded by experts in the fields of genetic medicine and RNA development and delivery, we have a dynamic operational structure designed to harness the ingenuity of a deep and diverse team of scientists, drug developers and business leaders.

Related People

3 contacts

Funding Insights

Based on industry data

VC-backed spending patterns

VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers

Tech investment trends